Cargando…
Health-Related Quality of Life and Survival in Metastasized Non-Small Cell Lung Cancer Patients with and without a Targetable Driver Mutation
SIMPLE SUMMARY: NSCLC patients with a targetable driver mutation are entitled to receive targeted therapy. Targeted therapy is usually less toxic than chemotherapy and immunotherapy. However, low-grade side effects are common and often chronic, which could also negatively impact a patient’s health-r...
Autores principales: | Billingy, Nicole E., Tromp, Vashti N. M. F., van den Hurk, Corina J. G., Becker-Commissaris, Annemarie, Walraven, Iris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428358/ https://www.ncbi.nlm.nih.gov/pubmed/34503092 http://dx.doi.org/10.3390/cancers13174282 |
Ejemplares similares
-
SYMptom monitoring with Patient-Reported Outcomes using a web application among patients with Lung cancer in the Netherlands (SYMPRO-Lung): study protocol for a stepped-wedge randomised controlled trial
por: Billingy, Nicole E, et al.
Publicado: (2021) -
Management of brain metastases in non-small cell lung cancer without actionable driver mutations—the need to dive deeper in the right ‘pool’
por: Jablonska, Paola Anna, et al.
Publicado: (2023) -
A Narrative Review on the Collection and Use of Electronic Patient-Reported Outcomes in Cancer Survivorship Care with Emphasis on Symptom Monitoring
por: van den Hurk, Corina J. G., et al.
Publicado: (2022) -
What is Currently the Best for Adenocarcinoma without Driver Mutation?
por: Park, Cheol-Kyu, et al.
Publicado: (2018) -
Individualized Nomogram for Predicting Survival in Patients with Brain Metastases After Stereotactic Radiosurgery Utilizing Driver Gene Mutations and Volumetric Surrogates
por: Zhou, Cheng, et al.
Publicado: (2021)